Loading...
Market
How will Novo Nordisk's market share change due to Ozempic's Alzheimer's potential by end of 2025?
2
Resolution / Starting Odds
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Market analysis reports from firms like Statista or Bloomberg
Story
Ozempic Linked to 70% Lower Alzheimer's Risk in Type 2 Diabetes Patients
Oct 24, 2024, 12:14 PM
Novo Nordisk's diabetes drug Ozempic, which contains the active ingredient semaglutide, has been linked to a significantly reduced risk of being diagnosed with Alzheimer's disease among people with type 2 diabetes. The observational study found a 70% lower risk of Alzheimer's diagnosis compared to other diabetes medications, based on an analysis of medical records. This adds to the growing evidence of Ozempic's effects beyond type 2 diabetes and obesity, indicating potential benefits in neurodegenerative diseases. Wegovy, another drug containing semaglutide, may also reduce Alzheimer's risk.
View original story
Similar markets
Increase by more than 10% • 25%
Increase by 5-10% • 25%
Increase by less than 5% • 25%
No significant change • 25%
Increase by over 10% • 25%
Increase by 5-10% • 25%
No significant change • 25%
Decrease • 25%
Increase by more than 20% • 25%
Increase by 10-20% • 25%
Increase by less than 10% • 25%
No significant change or decrease • 25%
Increase by over 5% • 25%
Increase by 1-5% • 25%
No significant change • 25%
Decrease • 25%
Adopted in US and EU • 25%
Adopted in US only • 25%
Adopted in EU only • 25%
Not adopted • 25%
Less than 25% • 25%
25-35% • 25%
35-45% • 25%
More than 45% • 25%
Yes • 50%
No • 50%
0 countries • 25%
1-5 countries • 25%
6-10 countries • 25%
More than 10 countries • 25%
No action taken • 25%
Safety label update • 25%
Product recall • 25%
Other regulatory actions • 25%
Less than 30% • 25%
30% to 40% • 25%
40% to 50% • 25%
More than 50% • 25%
Below 40% • 25%
40% - 50% • 25%
50% - 60% • 25%
Above 60% • 25%
Increased Sales • 25%
Decreased Sales • 25%
No Significant Change • 25%
Product Recall • 25%